{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:44:31Z","timestamp":1785350671305,"version":"3.55.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1038\/ncpendmet0497","type":"journal-article","created":{"date-parts":[[2007,4,23]],"date-time":"2007-04-23T14:14:01Z","timestamp":1177337641000},"page":"396-404","source":"Crossref","is-referenced-by-count":66,"title":["Management of Graves' ophthalmopathy"],"prefix":"10.1038","volume":"3","author":[{"given":"Wilmar M","family":"Wiersinga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncpendmet0497_CR1","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1210\/jc.2003-030430","volume":"88","author":"LJ Brokken","year":"2003","unstructured":"Brokken LJ et al. (2003) Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease. J Clin Endocrinol Metab 88: 4135\u20134138","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1365-2265.2000.00959.x","volume":"52","author":"MN Gerding","year":"2000","unstructured":"Gerding MN et al. (2000) Association of thyrotropin receptor autoantibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol 52: 267\u2013271","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0497_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/j.1365-2265.2004.02143.x","volume":"61","author":"AK Eckstein","year":"2004","unstructured":"Eckstein AK et al. (2004) Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol 61: 612\u2013619","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0497_CR4","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1210\/jc.2005-2813","volume":"91","author":"AK Eckstein","year":"2006","unstructured":"Eckstein AK et al. (2006) TSH-receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91: 3464\u20133470","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1089\/thy.1999.9.1175","volume":"9","author":"DHC Khoo","year":"1999","unstructured":"Khoo DHC et al. (1999) The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid 9: 1175\u20131180","journal-title":"Thyroid"},{"key":"BFncpendmet0497_CR6","doi-asserted-by":"crossref","unstructured":"The European Group on Graves' Orbitopathy (EUGOGO) (2006) Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155: 387\u2013389","DOI":"10.1530\/eje.1.02230"},{"key":"BFncpendmet0497_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1365-2265.2001.01349.x","volume":"55","author":"AJ Dickinson","year":"2001","unstructured":"Dickinson AJ and Perros P (2001) Controversies in the clinical evaluation of active thyroid associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol 55: 283\u2013303","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0497_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/archopht.123.4.491","volume":"123","author":"M Farid","year":"2005","unstructured":"Farid M et al. (2005) Psychological disturbance in Graves' ophthalmopathy. Arch Ophthalmol 123: 491\u2013496","journal-title":"Arch Ophthalmol"},{"key":"BFncpendmet0497_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","volume":"63","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ et al. (2005) Psychosocial morbidity of Graves' orbitopathy. Clin Endocrinol 63: 395\u2013402","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0497_CR10","unstructured":"EUGOGO European Group on Graves' Orbitopathy [ www.eugogo.org ] (accessed 8 March 2007)"},{"key":"BFncpendmet0497_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1046\/j.1365-2265.2001.01241.x","volume":"54","author":"CB Terwee","year":"2001","unstructured":"Terwee CB et al. (2001) Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QoL) after different treatments. Clin Endocrinol 54: 391\u2013398","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0497_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/01676830500192167","volume":"24","author":"WM Wiersinga","year":"2005","unstructured":"Wiersinga WM (2005) The philosophy of Graves' ophthalmopathy. Orbit 24: 165\u2013171","journal-title":"Orbit"},{"key":"BFncpendmet0497_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","volume":"269","author":"MF Prummel","year":"1993","unstructured":"Prummel MF and Wiersinga WM (1993) Smoking and risk of Graves' disease. JAMA 269: 479\u2013482","journal-title":"JAMA"},{"key":"BFncpendmet0497_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1530\/eje.1.01991","volume":"153","author":"GE Krassas","year":"2005","unstructured":"Krassas GE et al. (2005) Childhood Graves' ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 153: 515\u2013521","journal-title":"Eur J Endocrinol"},{"key":"BFncpendmet0497_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.7326\/0003-4819-129-8-199810150-00010","volume":"129","author":"L Bartalena","year":"1998","unstructured":"Bartalena L et al. (1998) Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med 129: 632\u2013635","journal-title":"Ann Intern Med"},{"key":"BFncpendmet0497_CR16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/bjo.87.6.773","volume":"87","author":"A Eckstein","year":"2003","unstructured":"Eckstein A et al. (2003) Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 87: 773\u2013776","journal-title":"Br J Ophthalmol"},{"key":"BFncpendmet0497_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","volume":"45","author":"J Pfeilschifter","year":"1996","unstructured":"Pfeilschifter J and Ziegler R (1996) Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol 45: 477\u2013481","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0497_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1530\/eje.1.02157","volume":"154","author":"GE Krassas","year":"2006","unstructured":"Krassas GE and Wiersinga WM (2006) Smoking and autoimmune thyroid disease: the plot thickens. Eur J Endocrinol 154: 777\u2013780","journal-title":"Eur J Endocrinol"},{"key":"BFncpendmet0497_CR19","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1089\/105072502761016476","volume":"12","author":"WM Wiersinga","year":"2002","unstructured":"Wiersinga WM and Bartalena L (2002) Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 12: 855\u2013860","journal-title":"Thyroid"},{"key":"BFncpendmet0497_CR20","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","volume":"150","author":"MF Prummel","year":"1990","unstructured":"Prummel MF et al. (1990) Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med 150: 1098\u20131101","journal-title":"Arch Intern Med"},{"key":"BFncpendmet0497_CR21","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","volume":"326","author":"L Tallstedt","year":"1992","unstructured":"Tallstedt L et al. (1992) Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 326: 1733\u20131738","journal-title":"N Engl J Med"},{"key":"BFncpendmet0497_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena L et al. (1998) Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 338: 73\u201378","journal-title":"N Engl J Med"},{"key":"BFncpendmet0497_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1210\/jcem.80.2.7852485","volume":"80","author":"CA Gorman","year":"1995","unstructured":"Gorman CA (1995) Radioiodine therapy does not aggravate Graves' ophthalmopathy. J Clin Endocrinol Metab 80: 340\u2013341","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1530\/eje.0.1300494","volume":"130","author":"L Tallstedt","year":"1994","unstructured":"Tallstedt L et al. (1994) Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 130: 494\u2013497","journal-title":"Eur J Endocrinol"},{"key":"BFncpendmet0497_CR25","first-page":"2986","volume":"81","author":"O T\u00f6rring","year":"1996","unstructured":"T\u00f6rring O et al. (1996) Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine\u2014prospective, randomized study. J Clin Endocrinol Metab 81: 2986\u20132993","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR26","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1210\/jc.2005-0507","volume":"90","author":"P Perros","year":"2005","unstructured":"Perros P et al. (2005) A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab 90: 5321\u20135323","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/eje.1.01924","volume":"153","author":"BE Jensen","year":"2005","unstructured":"Jensen BE et al. (2005) Glucocorticoids do not influence the effect of radioiodine therapy in Graves' disease. Eur J Endocrinol 153: 15\u201321","journal-title":"Eur J Endocrinol"},{"key":"BFncpendmet0497_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1046\/j.1365-2265.1999.00843.x","volume":"51","author":"C Marcocci","year":"1999","unstructured":"Marcocci C et al. (1999) The course of Graves' ophthalmopathy is not influenced by near-total thyroidectomy: a case\u2013control study. Clin Endocrinol 51: 503\u2013508","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0497_CR29","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1089\/thy.2005.15.1157","volume":"15","author":"J J\u00e4rhult","year":"2005","unstructured":"J\u00e4rhult J et al. (2005) Graves' disease with moderate\u2013severe endocrine ophthalmopathy\u2014long term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid 15: 1157\u20131164","journal-title":"Thyroid"},{"key":"BFncpendmet0497_CR30","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1089\/105072503322240004","volume":"13","author":"M Moletti","year":"2003","unstructured":"Moletti M et al. (2003) Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves' ophthalmopathy. Thyroid 13: 653\u2013658","journal-title":"Thyroid"},{"key":"BFncpendmet0497_CR31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/eje.1.02169","volume":"154","author":"S Ravzi","year":"2006","unstructured":"Ravzi S et al. (2006) What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol 154: 783\u2013786","journal-title":"Eur J Endocrinol"},{"key":"BFncpendmet0497_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2265.1995.tb02597.x","volume":"42","author":"P Perros","year":"1995","unstructured":"Perros P et al. (1995) Natural history of thyroid associated ophthalmopathy. Clin Endocrinol 42: 45\u201350","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0497_CR33","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","volume":"355","author":"MP Mourits","year":"2000","unstructured":"Mourits MP et al. (2000) Radiotherapy for Graves' orbitopathy; randomized placebo-controlled study. Lancet 355: 1505\u20131509","journal-title":"Lancet"},{"key":"BFncpendmet0497_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1210\/jc.2003-030809","volume":"89","author":"MF Prummel","year":"2004","unstructured":"Prummel MF et al. (2004) A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 89: 15\u201320","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/01676839609150235","volume":"15","author":"WM Wiersinga","year":"1996","unstructured":"Wiersinga WM (1996) Advances in medical therapy of thyroid-associated ophthalmopathy. Orbit 15: 177\u2013186","journal-title":"Orbit"},{"key":"BFncpendmet0497_CR36","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1046\/j.1365-2265.2000.00973.x","volume":"52","author":"MN Gerding","year":"2000","unstructured":"Gerding MN et al. (2000) Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol 52: 641\u2013646","journal-title":"Clin Endocrinol"},{"issue":"4","key":"BFncpendmet0497_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/bjo.2006.094607","volume":"91","author":"D. McKeag","year":"2006","unstructured":"Lazarus JH et al. (2006) Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol [doi: 10.1136\/bjo.2006.094607]","journal-title":"British Journal of Ophthalmology"},{"key":"BFncpendmet0497_CR38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1136\/bjo.83.4.463","volume":"83","author":"R Kalmann","year":"1999","unstructured":"Kalmann R and Mourits MP (1999) Diabetes mellitus: a risk factor in patients with Graves' orbitopathy. Br J Ophthalmol 83: 463\u2013465","journal-title":"Br J Ophthalmol"},{"key":"BFncpendmet0497_CR39","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","volume":"63","author":"IMMJ Wakelkamp","year":"2005","unstructured":"Wakelkamp IMMJ et al. (2005) Surgical or medical decompression as a first line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol 63: 323\u2013328","journal-title":"Clin Endocrinol"},{"key":"BFncpendmet0497_CR40","first-page":"102","volume":"85","author":"GJ Kahaly","year":"2000","unstructured":"Kahaly GJ et al. (2000) Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized single blind trial. J Clin Endocrinol Metab 85: 102\u2013108","journal-title":"Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR41","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0360-3016(02)03795-1","volume":"55","author":"J Gerling","year":"2003","unstructured":"Gerling J et al. (2003) Retrobulbar irradiation for thyroid associated orbitopathy: double blind comparison between 2.4 and 16 Gy. Int J Radiat Oncol Biol Phys 55: 182\u2013189","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFncpendmet0497_CR42","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1210\/jc.2003-030260","volume":"88","author":"C Marcocci","year":"2003","unstructured":"Marcocci C et al. (2003) Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 88: 3561\u20133566","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR43","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.ophtha.2003.12.054","volume":"111","author":"IMMJ Wakelkamp","year":"2004","unstructured":"Wakelkamp IMMJ et al. (2004) Orbital irradiation for Graves' ophthalmopathy. Is it safe? A long-term follow-up study. Ophthalmology 111: 1557\u20131562","journal-title":"Ophthalmology"},{"key":"BFncpendmet0497_CR44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","volume":"321","author":"MF Prummel","year":"1989","unstructured":"Prummel MF et al. (1989) Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 321: 1353\u20131359","journal-title":"N Engl J Med"},{"key":"BFncpendmet0497_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1046\/j.1365-2249.1996.d01-854.x","volume":"106","author":"G Kahaly","year":"1996","unstructured":"Kahaly G et al. (1996) Randomized trial of intravenous immunoglobulins versus prednisone in Graves' ophthalmopathy. Clin Exp Immunol 106: 197\u2013202","journal-title":"Clin Exp Immunol"},{"key":"BFncpendmet0497_CR46","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/0140-6736(93)92001-A","volume":"342","author":"MF Prummel","year":"1993","unstructured":"Prummel MF et al. (1993) Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 342: 949\u2013954","journal-title":"Lancet"},{"key":"BFncpendmet0497_CR47","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/S0161-6420(01)00632-7","volume":"108","author":"CA Gorman","year":"2001","unstructured":"Gorman CA et al. (2001) A prospective randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 108: 1523\u20131534","journal-title":"Ophthalmology"},{"key":"BFncpendmet0497_CR48","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1210\/jc.2004-1334","volume":"90","author":"JL W\u00e9meau","year":"2005","unstructured":"W\u00e9meau JL et al. (2005) Octreotide (long-acting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 90: 841\u2013848","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR49","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1210\/jc.2004-0697","volume":"89","author":"JA Dickinson","year":"2004","unstructured":"Dickinson JA et al. (2004) Double-blind, placebo-controlled trial of octreotide long-acting release (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 89: 5910\u20135915","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR50","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/BF03344124","volume":"29","author":"T-C Chang","year":"2006","unstructured":"Chang T-C and Lino S-L (2006) Slow-release lanreotide in Graves' opthalmopathy: a double blind, randomized, placebo-controlled clinical trial. J Endocrinol Invest 29: 413\u2013422","journal-title":"J Endocrinol Invest"},{"key":"BFncpendmet0497_CR51","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1210\/jc.2006-1105","volume":"91","author":"MN Stan","year":"2006","unstructured":"Stan MN et al. (2006) Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab 91: 4817\u20134824","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR52","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/BF03347943","volume":"14","author":"C Marcocci","year":"1991","unstructured":"Marcocci C et al. (1991) Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 14: 853\u2013860","journal-title":"J Endocrinol Invest"},{"key":"BFncpendmet0497_CR53","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","volume":"16","author":"G Kahaly","year":"1986","unstructured":"Kahaly G et al. (1986) Cyclosporin and prednisone vs prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 16: 415\u2013422","journal-title":"Eur J Clin Invest"},{"key":"BFncpendmet0497_CR54","first-page":"3562","volume":"86","author":"C Marcocci","year":"2001","unstructured":"Marcocci C et al. (2001) Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 86: 3562\u20133567","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR55","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ et al. (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 90: 5234\u20135240","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0497_CR56","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1034\/j.1600-0420.2002.800316.x","volume":"80","author":"R Kauppinen-M\u00e4kelin","year":"2002","unstructured":"Kauppinen-M\u00e4kelin R et al. (2002) High dose intravenous methylprednisolone therapy versus oral prednisone for thyoid-associated ophthalmopathy. Acta Ophthalmol Scand 80: 316\u2013321","journal-title":"Acta Ophthalmol Scand"},{"key":"BFncpendmet0497_CR57","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0002-9394(02)01970-0","volume":"135","author":"K Ohtsuka","year":"2003","unstructured":"Ohtsuka K et al. (2003) Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy. Am J Ophthalmol 135: 285\u2013290","journal-title":"Am J Ophthalmol"},{"key":"BFncpendmet0497_CR58","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1089\/thy.2000.10.521","volume":"10","author":"M Weissel","year":"2000","unstructured":"Weissel M and Hauff W (2000) Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease [letter]. Thyroid 10: 521","journal-title":"Thyroid"},{"key":"BFncpendmet0497_CR59","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1089\/105072504774193276","volume":"14","author":"M Marino","year":"2004","unstructured":"Marino M et al. (2004) Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 14: 403\u2013406","journal-title":"Thyroid"},{"key":"BFncpendmet0497_CR60","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1089\/1050725041692927","volume":"14","author":"M Salvi","year":"2004","unstructured":"Salvi M et al. (2004) Onset of autoimmune hepatitis during intravenous therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. Thyroid 14: 631\u2013634","journal-title":"Thyroid"},{"key":"BFncpendmet0497_CR61","unstructured":"LeMoli R et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid, in press"},{"key":"BFncpendmet0497_CR62","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/01.icu.0000139992.15463.1b","volume":"15","author":"PR Boulos","year":"2004","unstructured":"Boulos PR and Hardy I (2004) Thyroid-associated orbitopathy: a clinicopathologic and therapeutic review. Curr Opin Ophthalmol 15: 389\u2013400","journal-title":"Curr Opin Ophthalmol"},{"key":"BFncpendmet0497_CR63","first-page":"956","volume":"103","author":"GB Bartley","year":"1996","unstructured":"Bartley GB et al. (1996) Long-term follow-up of Graves' ophthalmopathy in an incidence cohort. Ophthalmology 103: 956\u2013962","journal-title":"Ophthalmology"},{"key":"BFncpendmet0497_CR64","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/112067210401400401","volume":"14","author":"FE Finamor","year":"2004","unstructured":"Finamor FE et al. (2004) Pentoxiphylline (PTX)\u2014an alternative treatment in Graves' ophthalmopathy (inactive phase): assessment by a disease specific quality of life questionnaire and by exopthalmometry in a prospective randomized trial. Eur J Ophthalmol 14: 277\u2013283","journal-title":"Eur J Ophthalmol"},{"key":"BFncpendmet0497_CR65","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","volume":"19","author":"D Paridaens","year":"2005","unstructured":"Paridaens D et al. (2005) The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 19: 1286\u20131289","journal-title":"Eye"},{"key":"BFncpendmet0497_CR66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1530\/eje.1.02325","volume":"156","author":"M Salvi","year":"2007","unstructured":"Salvi M et al. (2007) Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 156: 33\u201340","journal-title":"Eur J Endocrinol"}],"container-title":["Nature Clinical Practice Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0497","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:52:56Z","timestamp":1684439576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpendmet0497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["BFncpendmet0497"],"URL":"https:\/\/doi.org\/10.1038\/ncpendmet0497","relation":{},"ISSN":["1745-8366","1745-8374"],"issn-type":[{"value":"1745-8366","type":"print"},{"value":"1745-8374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}